Link between Mobotinib and Suvotinib

Mobocertinib and suvolitinib are two targeted drugs of important clinical significance in the treatment of non-small cell lung cancer (NSCLC). Although the two targets are different, there is an inherent connection between them, especially in terms of treatment strategies and resistance mechanisms.

Mobosetinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) mutations. It is mainly used to treat patients with non-small cell lung cancer carrying EGFR Exon 20 insertion mutations. Unlike traditional EGFR inhibitors (such as erlotinib and gefitinib), mobosetinib is specifically designed to overcome resistance caused by certain mutations. It has shown good anti-tumor activity in clinical trials, especially in patients who are resistant to existing EGFR-targeted therapies.

Suvotinib is an inhibitor that targetsMET receptor tyrosine kinase and is mainly used to treat metastatic non-small cell lung cancer with MET exon 14 skipping changes. In patients whose disease has progressed after platinum-based chemotherapy or who cannot tolerate platinum-based chemotherapy, suvotinib achieves anti-tumor effects by inhibiting the MET signaling pathway and preventing the proliferation and survival of tumor cells. Suvotinib was approved in China based on favorable results in a pivotal Phase II trial showing its effectiveness in a specific group of patients with genetic alterations.

During the treatment of non-small cell lung cancer, patients may undergo multiple treatments. As the disease progresses, tumor cells may develop new mutations, causing the original treatment to become ineffective. In this case, mobosetinib may initially be effective, but if the patient develops resistance to the drug, suvotinib becomes a potential subsequent treatment option. Such a treatment sequence reflects the adoption of precision medicine in tumor treatment, which is to continuously adjust treatment strategies based on the patient's genetic characteristics and disease status.

In addition, studies have shown thatEGFR and MET signaling pathways interact in many patients with non-small cell lung cancer, and activation of MET may be related to resistance to EGFR inhibitors. Therefore, therapies targeting the MET pathway, such as suvotinib, may have better therapeutic effects in patients who have developed resistance to EGFR inhibitors. This promotes the combined use of targeted drugs, which both improves the effectiveness of treatment and provides patients with more treatment options.

In clinical practice, targeted therapies targeting different molecular characteristics have gradually become the standard, and doctors will comprehensively consider the patient's genetic test results when selecting treatment options. For example, for aFor patients with positive EGFR mutations, if resistance is found during follow-up after the first use of mobosertinib, doctors may recommend MET testing. If MET exon 14 skipping mutations are found, suvotinib may be considered. This molecular marker-based treatment selection not only improves the success rate of treatment, but also reduces the side effects and economic burden caused by ineffective treatments.